Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5790 Target Snapshot

Cyclin-dependent kinase 17 · SINGLE PROTEIN · Homo sapiens

449Compounds
129Assays
10Approved Drugs
348.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q00537. Use UniProt Q00537 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q00537 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 17 as ChEMBL target CHEMBL5790, mapped to UniProt Q00537. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 17
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5790
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q00537
Cyclin-dependent kinase 17
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 17 is the right protein anchor across sources, using UniProt Q00537 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 17
UniProt AccessionQ00537
Component TypeProtein
Sequence Length523 aa

Cyclin-dependent kinase 17

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 17, mapped to UniProt Q00537. Sequence length is 523 aa.

Mapped IDQ00537
Review nameCyclin-dependent kinase 17
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
4
Phase III
10
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC507.0
KD341.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL384304 9.07 Kd 0.86 Clinical
CHEMBL445813 9.02 Kd 0.95 Clinical
CHEMBL296468 8.7 Kd 2.0 Preclinical
CHEMBL3545085 8.3 Kd 5.0 Preclinical
CHEMBL428690 8.22 Kd 6.0 Clinical
CHEMBL1738757 8.15 Kd 7.0 Clinical
CHEMBL482967 8.15 Kd 7.0 Preclinical
CHEMBL3128043 7.85 Kd 14.0 Preclinical
CHEMBL574738 7.82 Kd 15.0 Preclinical
CHEMBL2028663 7.44 Kd 36.0 Approved
Distribution

pChEMBL Value Distribution

1
5.0
17
5.5
15
6.0
4
6.5
6
7.0
5
7.5
5
8.0
1
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
NINTEDANIB
CHEMBL502835
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
REGORAFENIB
CHEMBL1946170
Approved 2012
Assay Landscape

Assay Landscape

129
Total Assays
48
Tested Compounds
1
Assay Types
Binding — 129 assays, 48 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 67 29 6.4
cell-based format 23 0
subcellular format 23 19 7.0
assay format 16 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine